BSE Live
Mar 23, 11:57Prev. Close
82.95
Open Price
84.80
Bid Price (Qty.)
86.30 (507)
Offer Price (Qty.)
86.39 (5)
NSE Live
Dec 27, 11:22Prev. Close
-
Open Price
-
Bid Price (Qty.)
- (0)
Offer Price (Qty.)
- (0)
| Key Financial Ratios of Godavari Drugs (in Rs. Cr.) | Mar 20 | Mar 19 | Mar 18 | Mar 17 | Mar 16 | |
| Per Share Ratios | ||||||
| Basic EPS (Rs.) | 2.66 | 1.60 | 1.10 | 2.40 | 1.79 | |
| Diluted EPS (Rs.) | 2.66 | 1.60 | 1.10 | 2.40 | 1.79 | |
| Cash EPS (Rs.) | 4.20 | 3.05 | 2.41 | 3.47 | 2.63 | |
| Book Value [ExclRevalReserve]/Share (Rs.) | 26.90 | 24.24 | 22.64 | 21.54 | 19.14 | |
| Book Value [InclRevalReserve]/Share (Rs.) | 26.90 | 24.24 | 22.64 | 21.54 | 19.14 | |
| Dividend / Share(Rs.) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Revenue from Operations/Share (Rs.) | 127.08 | 110.94 | 85.58 | 100.39 | 94.44 | |
| PBDIT/Share (Rs.) | 8.45 | 7.60 | 6.26 | 8.00 | 6.22 | |
| PBIT/Share (Rs.) | 6.91 | 6.16 | 4.96 | 6.93 | 5.39 | |
| PBT/Share (Rs.) | 3.04 | 2.32 | 1.74 | 3.60 | 2.89 | |
| Net Profit/Share (Rs.) | 2.66 | 1.60 | 1.10 | 2.40 | 1.79 | |
| Profitability Ratios | ||||||
| PBDIT Margin (%) | 6.64 | 6.85 | 7.31 | 7.96 | 6.58 | |
| PBIT Margin (%) | 5.43 | 5.54 | 5.79 | 6.90 | 5.70 | |
| PBT Margin (%) | 2.39 | 2.08 | 2.03 | 3.58 | 3.06 | |
| Net Profit Margin (%) | 2.09 | 1.44 | 1.28 | 2.39 | 1.89 | |
| Return on Networth / Equity (%) | 9.87 | 6.61 | 4.86 | 11.15 | 9.37 | |
| Return on Capital Employed (%) | 15.91 | 16.30 | 14.56 | 23.50 | 6.98 | |
| Return on Assets (%) | 2.38 | 1.61 | 1.31 | 3.24 | 2.67 | |
| Total Debt/Equity (X) | 1.29 | 1.15 | 1.06 | 0.97 | 1.07 | |
| Asset Turnover Ratio (%) | 114.03 | 111.91 | 102.25 | 135.72 | 140.70 | |
| Liquidity Ratios | ||||||
| Current Ratio (X) | 1.19 | 1.24 | 1.26 | 1.27 | 1.29 | |
| Quick Ratio (X) | 0.84 | 0.89 | 0.90 | 0.93 | 0.95 | |
| Inventory Turnover Ratio (X) | 5.39 | 5.07 | 4.78 | 6.68 | 6.62 | |
| Dividend Payout Ratio (NP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Dividend Payout Ratio (CP) (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cash Earnings Retention Ratio (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Valuation Ratios | ||||||
| Enterprise Value (Cr.) | 33.35 | 37.07 | 40.32 | 37.11 | 43.74 | |
| EV/Net Operating Revenue (X) | 0.35 | 0.44 | 0.63 | 0.49 | 0.62 | |
| EV/EBITDA (X) | 5.24 | 6.48 | 8.55 | 6.16 | 9.34 | |
| MarketCap/Net Operating Revenue (X) | 0.09 | 0.21 | 0.37 | 0.38 | 0.41 | |
| Retention Ratios (%) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Price/BV (X) | 0.43 | 0.96 | 1.40 | 1.76 | 2.01 | |
| Price/Net Operating Revenue | 0.09 | 0.21 | 0.37 | 0.38 | 0.41 | |
| Earnings Yield | 0.23 | 0.07 | 0.03 | 0.06 | 0.05 |
25.02.2026
Godavari Drugs Standalone December 2025 Net Sales at Rs 22.18 crore, down 24.93% Y-o-Y
24.11.2025
Godavari Drugs Standalone September 2025 Net Sales at Rs 26.65 crore, up 2.15% Y-o-Y
10.06.2025
Godavari Drugs Standalone March 2025 Net Sales at Rs 25.50 crore, down 34% Y-o-Y
17.02.2025
Godavari Drugs Standalone December 2024 Net Sales at Rs 29.55 crore, down 31.45% Y-o-Y
25.02.2026
Godavari Drugs Standalone December 2025 Net Sales at Rs 22.18 crore, down 24.93% Y-o-Y
24.11.2025
Godavari Drugs Standalone September 2025 Net Sales at Rs 26.65 crore, up 2.15% Y-o-Y
10.06.2025
Godavari Drugs Standalone March 2025 Net Sales at Rs 25.50 crore, down 34% Y-o-Y
17.02.2025
Godavari Drugs Standalone December 2024 Net Sales at Rs 29.55 crore, down 31.45% Y-o-Y
23.03.2026
Alkem Laboratories gets DCGI nod for Semaglutide Injection; share price fall marginally
23.03.2026
22.03.2026
Sell-on-rise market? SBI Securities sees Nifty under pressure, picks two stocks for the week ahead
20.03.2026
Eris Lifesciences, Natco Pharma to launch generic Ozempic at 90% cheaper price
21.01.2026
Dr Reddy's posts smaller-than-expected Q3 profit fall on domestic boost
12.11.2025
07.11.2025
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
17.07.2025
Sun Pharma Q1 PAT seen up 8.4% YoY to Rs 3,132.7 cr: ICICI Securities
17.07.2025
Biocon Q1 PAT may dip 72% YoY to Rs 91.1 cr: ICICI Securities
17.07.2025
Cipla Q1 PAT seen up 2% YoY to Rs 1,246.7 cr: ICICI Securities
29.01.2025
Sun Pharma Q3 Preview: Double-digit India, US sales to power mid-teen profit growth